← All trials
NCT04314219
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2020
- Primary completion
- Feb 23, 2024
- Completion date
- Dec 29, 2025
- First posted
- Mar 19, 2020
- Last posted
- Mar 19, 2020
- Enrollment
- 264
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- King Faisal UniversityLead sponsor
- King Faisal Specialist HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.